In breast cancer, Ye et al. found that the restoration of Spalt-like transcription factor 2 (SALL2) is mediated by DNMT inhibition, which can make tamoxifen-resistant breast cancer sensitive to tamoxifen therapy again. Here, SALL2 is linked to breast carcinoma.